Cardiology MCQ 179: Abciximab

Which of the following is not true about abciximab?

a) Glycoprotein IIb/IIIa blocker

b) Orally active

c) Monoclonal

d) Used as an adjunct in PCI


["Click here for the answer with explanation", "Correct Answer:"]

b) Orally active

Abciximab is an intravenous glycoprotein IIb/IIIa blocker which is a monoclonal antibody, useful as an adjunct in percutaneous coronary intervention when there is a thrombus load in the coronary artery. Glycoprotein IIb/IIIa is the receptor in the final common pathway for platelet activation.

Add a Comment

Your email address will not be published. Required fields are marked *